Maitreya Medicare Ltd

AI
Maitreya Medica. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Maitreya Medicare Ltd

₹ 131 -9.06%
26 Oct - close price
maitreyahospitals.com NSE - SME: MAITREYA
About

Incorporated in 2019, Maitreya Medicare Ltd is an integrated multispeciality hospital with primary secondary & tertiary care situated in Surat, Gujrat.[1]

Key Points

Business Overview:[1]
MML is a Surat-based multi-super speciality hospital with a 125-bed capacity and a 50-bed capacity in its subsidiary, Tulip Health Check. Its facility offers a wide range of integrated healthcare services, spanning primary, secondary, and tertiary care. These
include Gastroenterology, Nephrology, General & Laparoscopic Surgery, Urology, Oncology, Oncosurgery, Gynecology and High-Risk Obstetrics, Emergency & Trauma, Cardiology, Orthopedic & Joint Replacement Surgery, Cardiothoracic and Vascular Surgery, Neurology, Critical Care Medicine, Neurosurgery, Spine Surgery, Gastrointestinal Surgery, and Cardiothoracic Surgery, Orthopedic Surgery (Including Joint Replacements and Arthroscopic Surgeries), Hepatocellular Biliary Surgery, etc.

Website NSE - SM
  • Market Cap ₹ 89.1 Cr.
  • Current Price ₹ 131
  • High / Low ₹ 293 / 103
  • Stock P/E 1,781
  • Book Value ₹ 46.7
  • Dividend Yield 0.00 %
  • ROCE 0.11 %
  • ROE -4.87 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company's working capital requirements have reduced from 46.7 days to 22.1 days

Cons

  • Stock is trading at 2.82 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -5.77% over past five years.
  • Company has a low return on equity of 5.46% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Hospital

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026 Sep 2026
24.28 22.25 22.18 22.23 23.28 20.94 23.65
19.86 20.51 19.45 20.08 22.11 21.52 19.99
Operating Profit 4.42 1.74 2.73 2.15 1.17 -0.58 3.66
OPM % 18.20% 7.82% 12.31% 9.67% 5.03% -2.77% 15.48%
0.05 0.17 0.14 0.30 0.14 0.59 0.33
Interest 0.39 0.35 0.38 0.37 0.37 0.91 1.04
Depreciation 0.63 0.63 0.63 0.71 0.71 0.67 0.88
Profit before tax 3.45 0.93 1.86 1.37 0.23 -1.57 2.07
Tax % 28.99% 22.58% 27.42% 59.12% 34.78% -5.73% 26.57%
2.45 0.72 1.35 0.55 0.15 -1.47 1.52
EPS in Rs 4.94 1.06 1.99 0.81 0.22 -2.17 2.24
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
8.40 55.73 48.14 38.38 44.85 42.74 41.40 44.59
7.74 48.42 45.21 31.22 38.69 37.86 40.70 41.51
Operating Profit 0.66 7.31 2.93 7.16 6.16 4.88 0.70 3.08
OPM % 7.86% 13.12% 6.09% 18.66% 13.73% 11.42% 1.69% 6.91%
0.04 0.46 0.44 0.52 0.22 0.44 0.68 0.92
Interest 0.31 0.79 0.76 0.57 0.74 0.75 1.28 1.95
Depreciation 0.34 1.00 1.20 1.27 1.26 1.35 1.38 1.55
Profit before tax 0.05 5.98 1.41 5.84 4.38 3.22 -1.28 0.50
Tax % 220.00% 26.09% 24.11% 28.25% 27.85% 40.99% 3.91%
-0.06 4.41 1.07 4.19 3.17 1.90 -1.32 0.05
EPS in Rs -0.12 8.82 2.14 8.45 4.68 2.80 -1.95 0.07
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: -6%
3 Years: 3%
TTM: -2%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -93%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -47%
Return on Equity
10 Years: %
5 Years: 11%
3 Years: 5%
Last Year: -5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 0.01 0.01 0.01 4.96 6.78 6.78 6.78 11.46
Reserves -0.05 4.36 5.48 3.82 18.08 19.98 18.66 20.18
12.13 14.24 12.38 11.59 9.46 8.85 27.66 22.41
2.30 7.28 4.96 7.38 6.20 8.80 10.19 10.34
Total Liabilities 14.39 25.89 22.83 27.75 40.52 44.41 63.29 64.39
9.33 13.81 13.50 11.51 10.94 11.97 33.09 32.67
CWIP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Investments 0.41 1.54 0.36 0.70 3.61 7.63 7.63 7.61
4.65 10.54 8.97 15.54 25.97 24.81 22.57 24.11
Total Assets 14.39 25.89 22.83 27.75 40.52 44.41 63.29 64.39

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1.23 4.91 0.77 2.42 -0.26 5.03 5.48
-12.17 -5.63 0.16 0.36 -5.57 -7.20 -22.42
11.88 1.51 -2.61 -1.34 10.00 -1.58 17.92
Net Cash Flow 0.94 0.79 -1.68 1.43 4.18 -3.75 0.98
Free Cash Flow -8.44 -0.57 -0.12 2.99 -0.94 2.66 -17.03
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 152% 78% 26% 38% 25% 133% 800%

Ratios

Standalone / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 31.72 30.78 40.94 88.06 106.37 129.72 102.45
Inventory Days 171.39 62.04 40.82 69.86 29.89 29.95 59.17
Days Payable 558.61 230.96 221.25 317.85 149.43 173.45 251.27
Cash Conversion Cycle -355.50 -138.13 -139.49 -159.93 -13.18 -13.78 -89.66
Working Capital Days 0.87 4.13 16.83 26.63 60.30 57.56 22.13
ROCE % 43.19% 11.40% 33.68% 18.61% 11.30% 0.11%

Insights

In beta
Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Bed Capacity
beds

Log in to view insights

Please log in to see hidden values.

Login
ARPOB (Average Revenue Per Occupied Bed)
INR
Bed Occupancy Rate
%
Number of Hospitals
hospitals
Inpatient Volume
patients
Number of Specialties
specialties
Outpatient Volume
patients

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026Sep 2026
73.11% 73.11% 73.11% 73.00% 73.11% 73.11%
2.53% 0.41% 0.01% 0.00% 0.00% 0.00%
1.35% 0.00% 0.00% 0.00% 0.00% 0.00%
23.02% 26.48% 26.88% 27.00% 26.89% 26.89%
No. of Shareholders 4749079869789761,024

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls

  • Nov 2025
    Transcript
    AI Summary
    PPT
  • Sep 2025
    Transcript
    AI Summary
    PPT
  • Nov 2024
    Transcript PPT
  • May 2024
    Transcript
    AI Summary
    PPT
  • Feb 2024
    Transcript PPT